Merck + Co., Inc.

Merck Sharp + Dohme Corp.

Conrad Santini

Soumya P Sahoo

Richard L Tolman

Alan D Adams

Gregory D Berger

Jeffrey P Bergman

Victoria K Lombardo

Julia K Boueres

Wei Han

Tesfaye Biftu

Harold B Wood

Ranjit C Desai

Joel Peter Berger

Jason W Szewczyk

Chan-Hwa Kuo

David E Moller

Stanley Leon Freeman

Yong Huang

Mark D Leibowitz

Dominick F Gratale

Robert M Burk

Arthur A Patchett

Thomas F Walsh

William H Parsons

Donald W Graham

James V Heck

Mitree M Ponpipom

Robert L Bugianesi

Derek J Von Langen

John J Acton, Iii

Richard B Toupence

Kenneth J Fitch

Yuan-Ching P Chiang

Narindar N Girotra

Claude Dufresne

James D Bergstrom

Edward J Metzger

Robert W Marquis, Jr

Ralph Troy Mosley

Anthony B Jones

Lori L Whiting

Sandra P Plevyak

Jonthan R Young

Bipiperidinyl compounds of the formula: are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. Pharmaceutically acceptable salts and solvates are included as well. The compounds are useful as agonists of the g-protein coupled receptor GPR-119.

Bipiperidinyl compounds, compositions, containing such compounds and methods of treatment

Bipiperidyl compounds of the formula: (I) are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. Pharmaceutically acceptable salts and solvates are included as well. The compounds are useful as agonists of the g-protein coupled receptor GPR-119. 

Acyl bipiperidinyl compounds useful as GPR 119 agonists

Substituted 5-aryl-2,4-thiazolidinediones or 5-aryl-2,4-oxazolidinediones that also carry a second substituent in the 5-position of the heterocyclic ring are potent agonists of PPAR, and are therefore useful in the treatment, control or prevention of diabetes, hyperglycemia, hyperlipidemia (including hypercholesterolemia and hypertriglyceridemia), atherosclerosis, obesity, vascular restenosis, and other PPAR &agr;, &dgr; and/or &ggr; mediated diseases, disorders and conditions.

Arylthiazolidinedione and aryloxazolidinedione derivatives

Substituted 5-aryl-2,4-thiazolidinediones are potent agonists of PPAR, and are therefore useful in the treatment, control or prevention of diabetes, hyperglycemia, hyperlipidemia (including hypercholesterolemia and hypertriglyceridemia), atherosclerosis, obesity, vascular restenosis, and other PPAR &agr;, &dgr; and/or &ggr; mediated diseases, disorders and conditions.

Arylthiazolidinedione derivitives

The instant invention is concerned with acetylphenols which are useful as antiobesity and antidiabetic compounds. Compositions and methods for the use of the compounds in the treatment of diabetes and obesity and for lowering or modulating triglyceride levels and cholesterol levels or raising high density lipoprotein levels or for increasing gut motility or for treating atherosclerosis are also disclosed.

Benzisoxazole-derived antidiabetic compounds

Substituted 5-aryl-2,4-thiazolidinediones are potent agonists of PPAR, and are therefore useful in the treatment, control or prevention of diabetes, hyperglycemia, hyperlipidemia (including hypercholesterolemia and hypertriglyceridemia), atherosclerosis, obesity, vascular restenosis, and other PPAR .alpha., .delta. and/or .gamma. mediated diseases, disorders and conditions.

Arylthiazolidinedione derivatives

Antidiabetic agents

Cholesterol lowering compounds

This invention is directed to compounds of formula (I) which are novel C3- or C5-acyl sulfonamide, carboxamic acid or tetrazolyl analogs of the Zaragozic acids. These compounds inhibit the enzyme squalene synthase and are useful as cholesterol lowering agents. ##STR1##

There is disclosed a process for preparing aldehydes from base sensitive amines. The process can be employed to obtain carboxylic acid methyl esters. In particular, thiazolidine carboxylic methyl ester can be produced which is useful as an intermediate in the preparation of bicyclic lactam compounds. These bicyclic lactam compounds are potent angiotesin converting enzyme (ACE) inhibitors useful in the treatment of hypertension, congestive heart failure, and the like.

Process for preparing aldehydes from base sensitive amines

Growing community of inventors

Warren, NJ, United States of America

Conrad Santini